


Roxindole

Chemical Properties

| | |
|-------------------|---|
| CAS No. : | 112192-04-8 |
| Formula: | C ₂₃ H ₂₆ N ₂ O |
| Molecular Weight: | 346.47 |
| Storage: | Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA. |



Biological Description

| | |
|----------------------------|---|
| Description | Roxindole (EMD 49980) is a selective dopamine autoreceptor and 5-HT _{1A} dual agonist and inhibitor of 5-hydroxytryptamine (5-HT) uptake with antipsychotic and antidepressant activity. Roxindole can be used to study Parkinson's and neurodivergence. |
| Targets(IC ₅₀) | 5-HT Receptor, Dopamine Receptor, Serotonin Transporter |
| In vitro | Roxindole has high affinity for hD ₃ as well as hD ₂ (short isomer) and hD ₄ (4-repeat isomer) receptors (pK _i values of 8.93, 8.55 and 8.23, respectively). In addition, it had a high affinity for the h5-HT _{1A} receptor (pK _i = 9.42), but a low affinity for the 5-HT _{1B} and 5-HT _{1D} receptors (pK _i values of 6.00 and 7.05, respectively). [1] |
| In vivo | Roxindole (EMD 49980) inhibited apomorphine-induced climbing behavior in mice and stereotyped behavior in rats with ED ₅₀ of 1.4 mg/kg s.c. and 0.65 mg/kg s.c., respectively, and also inhibited conditioned avoidance responses in rats (ED ₅₀ = 1.5 mg/kg s.c) [2]; In the paradigm of co-treatment with haloperidol (1 mg/kg per day, orally), Roxindole (EMD 49980) (10 mg/kg per day, orally) did not alter the behavioral hypersensitivity measured after the drug washout phase as compared with the effect of haloperidol alone; if administration of Roxindole (EMD 49980) (10 mg/kg, i.v.) after the drug washout phase induced only weak stereotyped behaviors in haloperidol-hypersensitized rats, Roxindole (EMD 49980) did not induce either desensitization of the presynaptic or supersensitivity of the postsynaptic dopamine D ₂ receptor[3]; Roxindole (EMD 49980) (1, 3, 10 mg/kg; s.c) inhibits both effects of 8-OH-DPAT (flattened body and forepaw stamping) in normal rats (male Wistar 200-350g) [5]. |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 2.8863 mL | 14.4313 mL | 28.8625 mL |
| 5 mM | 0.5773 mL | 2.8863 mL | 5.7725 mL |
| 10 mM | 0.2886 mL | 1.4431 mL | 2.8863 mL |
| 50 mM | 0.0577 mL | 0.2886 mL | 0.5773 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Newman-Tancredi A, et al.. Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. *Naunyn Schmiedeberg's Arch Pharmacol.* 1999 Jun;359(6):447-53.

Maj J, et al. Roxindole, a potential antidepressant. I. Effect on the dopamine system. *J Neural Transm (Vienna)*. 1996;103(5):627-41.

Seyfried CA, et al. Sensitivity of dopamine D2 receptors following long-term treatment with roxindole. *Eur J Pharmacol.* 1994 May 12;257(1-2):67-72.

Gründer G, et al. The neuroendocrinological profile of roxindole, a dopamine autoreceptor agonist, in schizophrenic patients. *Psychopharmacology (Berl)*. 1995 Feb;117(4):472-8.

Maj J, et al. Roxindole, a dopamine autoreceptor agonist with a potential antidepressant activity. II. Effects on the 5-hydroxytryptamine system. *Pharmacopsychiatry.* 1997 Mar;30(2):55-61.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481